|
Abstract
|
Breast and uterine cancers represent two of the most common and clinically significant malignancies affecting women worldwide. Despite advances in diagnosis and treatment, these cancers continue to pose major challenges due to their biological heterogeneity, variable clinical behavior, and differences in treatment response. Understanding the molecular mechanisms underlying these cancers is therefore essential for improving patient outcomes.
The retinoblastoma (RB1) gene and the p53 gene are among the most critical tumor suppressor genes involved in the regulation of the cell cycle, DNA repair, and apoptosis. Alterations in these genes are frequently associated with tumor initiation, progression, and resistance to therapy. However, the molecular interaction between retinoblastoma proteins and p53, particularly when compared across different cancer types such as breast and uterine cancers, remains insufficiently explored.
This research is necessary because it provides a comparative genetic analysis of retinoblastoma protein alterations in two hormonally influenced cancers using the p53 gene as a reference point. Such a comparison can reveal whether similar or distinct molecular pathways contribute to tumor development in these cancers. Identifying these differences is crucial for understanding cancer-specific mechanisms rather than relying on generalized models of tumor biology.
Furthermore, this study holds importance in the context of early diagnosis and prognosis. Aberrant expression of pRb and p53 has been linked to tumor aggressiveness, stage, and patient survival. By clarifying their genetic relationship in breast and uterine cancers, this research may help identify reliable molecular markers that can be used to predict disease progression and guide clinical decision-making.
From a therapeutic perspective, targeting cell cycle regulatory pathways has become an important strategy in cancer treatment. A deeper understanding of pRb–p53 pathway alterations may suppo
|